Barclays Maintains Overweight on Insmed, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Leon Wang maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $37 to $40.
April 11, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Insmed and raises the price target from $37 to $40.
The upgrade in price target by Barclays, a major financial institution, reflects a positive outlook on Insmed's future performance. This is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100